Últimas noticias sobre Vir Biotechnology (NASDAQ:VIR) Bolsa

VIR BIOTECHNOLOGY INC

Vir Biotechnology

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Vir Biotechnology Inc

Viratech Corp

Neuralbase AI Ltd

Virco Manufacturing Corporation - Common Stock

Virco Manufacturing Corp

Viridien

Pacer Funds Trust BioThreat Strategy ETF

Virtu Financial, Inc. - Class A Common Stock

Virtu Financial Inc

VIRACTA THERAPEUTICS INC by Viracta Therapeutics, Inc.

Viracta Therapeutics Inc

The most oversold stocks in the information technology sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">CPI Card Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>)</h3>
<ul class="wp-block-list">
<li>On May 7, CPI Card reported worse-than-expected first-quarter earnings. &#8220;We are pleased with our first quarter sales performance, led by strong growth from our debit and credit card portfolio,&#8221; said John Lowe, President and Chief Executive Officer. &#8220;Our outlook remains intact, and we plan to continue to execute our strategies to gain share and diversify our business, as evidenced by our acquisition of Arroweye Solutions.&#8221; The company's stock fell around 22% over the past five days and has a 52-week low of $18.46.</li>
<li>RSI Value: 29.4</li>
<li>PMTS Price Action: Shares of CPI Card fell 4.8% to close at $20.48 on Monday.</li>
<li>Edge Stock Ratings: 26.27 Momentum score with Value at 43.86. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/PMTS"><img loading="lazy" decoding="async" width="470" height="172" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042818/image-134.png" alt="" class="wp-image-913102" style="width:372px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042818/image-134.png 470w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042818/image-134-300x110.png 300w" sizes="(max-width: 470px) 100vw, 470px" /></a></figure>
<h3 class="wp-block-heading">Astrotech Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTC#NASDAQ">ASTC</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On Feb. 14, Astrotech reported its financial results for the second quarter of fiscal year 2025, which ended Dec. 31, 2024. Thomas B. Pickens, III, Astrotech&#8217;s Chairman, Chief Executive Officer and Chief Technology Officer, said &#8220;We are now prioritizing and accelerating our attention to selling and marketing our line of portable, rugged and inexpensive mass spectrometry instruments. We believe 1st Detect&#8217;s explosive trace detection products are now proven with four years of use in cargo warehouses having run thousands of samples at airports in 14 countries.&#8221; The company's stock fell around 16% over the past six months and <a href="https://www.benzinga.com/quote/ASTC">has a 52-week low</a> of $5.72.</li>
<li>RSI Value: 26.1</li>
<li>ASTC Price Action: Shares of Astrotech gained 2.3% to close at $5.90 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0513">ASTC stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0513"><img loading="lazy" decoding="async" width="922" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042933/image-135.png" alt="" class="wp-image-913105" style="width:523px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042933/image-135.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042933/image-135-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13042933/image-135-768x701.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">reAlpha Tech Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>)</h3>
<ul class="wp-block-list">
<li>On April 28, reAlpha Tech announced the appointment of Cristol Rippe as Chief Marketing Officer. &#8220;Cristol&#8217;s arrival marks an exciting new chapter for the reAlpha executive team,&#8221; said Mike Logozzo, President and Chief Operating Officer of reAlpha. The company's stock fell around 16% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/AIRE">low of $0.51.</a></li>
<li>RSI Value: 29.2</li>
<li>AIRE Price Action: Shares of reAlpha Tech fell 0.1% to close at $0.58 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0513">AIRE shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0513"><img loading="lazy" decoding="async" width="868" height="821" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13043038/image-136.png" alt="" class="wp-image-913108" style="width:616px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13043038/image-136.png 868w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13043038/image-136-300x284.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13043038/image-136-768x726.png 768w" sizes="(max-width: 868px) 100vw, 868px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

AIRE

ASTC

PMTS

Top 3 Tech Stocks Which Could Rescue Your Portfolio This Quarter

WIIM

Honda Motor shares are trading lower after the company reported a year-over-year decrease in FY25 GAAP EPS results.

ONON

On Holding shares are trading higher after the company reported better-than-expected Q1 financial results.

Immatics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMTX#NASDAQ">IMTX</a>) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.33) by 6.06 percent. This is a 713.95 percent decrease over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $19.54 million which beat the analyst consensus estimate of $15.42 million by 26.73 percent. This is a 40.56 percent decrease over sales of $32.87 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

IMTX

Immatics Q1 EPS $(0.35) Misses $(0.33) Estimate, Sales $19.54M Beat $15.42M Estimate

WestPark Capital analyst Casey Ryan reiterates Innoviz Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVZ#NASDAQ">INVZ</a>) with a Buy and maintains $2.22 price target.

Price Target

Reiteration

Analyst Ratings

INVZ

WestPark Capital Reiterates Buy on Innoviz Technologies, Maintains $2.22 Price Target

UnitedHealth Group shares are trading lower. The company announced the appointment of Stephen Hemsley as CEO.

<ul>
<li>WonderFi will join Robinhood Crypto and continue to deliver crypto products to Canadian customers</li>
<li>WonderFi shareholders to receive all-cash consideration of C$0.36 per Common Share</li>
<li>Purchase price represents an attractive premium of approximately 41% to the closing price, and 71% to the 30-day VWAP, as of May 12</li>
</ul>

HOOD

Robinhood To Acquire WonderFi, A Canadian Crypto Platform, For C$250M In All-Cash Deal At C$0.36 Per Share

New BD FACSDiscover&#x2122; A8 Cell Analyzer Brings Leading-Edge Capabilities to Wider Range of Scientists across Academia and Biopharma
FRANKLIN LAKES, N.J., May 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>), a leading global medical technology company, announced the global commercial launch of the world's first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, enabling more researchers across a wider range of applications to uncover deeper insights and dynamics from cells once invisible in flow cytometry experiments – with increased ease and throughput.

BD Launches FACSDiscover A8 Cell Analyzer, Featuring Spectral And Real-Time Cell Imaging Technologies For Scientists In Academia And Biopharma

Needham analyst Charles Shi reiterates Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) with a Buy and maintains $325 price target.

CDNS

Needham Reiterates Buy on Cadence Design Systems, Maintains $325 Price Target

COIN

Coinbase Global shares are trading higher it was announced that the company will join the S&P 500, effective before the opening of trading on Monday, May 19.

Sea shares are trading higher after the company reported better-than-expected Q1 EPS results.

On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) FY2025 Revenue expected to be at least CHF 2.86 billion.

Guidance

On Holding FY2025  Revenue expected to be at least CHF 2.86 billion.

Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 81.08 percent increase over losses of $(0.74) per share from the same period last year.

CLRB

Cellectar Biosciences Q1 EPS $(0.14) Beats $(0.16) Estimate, Cash $13.9M

Biotech

General

SKYE

Skye Bioscience Presented A Clinical Model On Peripheral CB1 Inhibition For Weight Loss At European Congress On Obesity

Rogers Sugar (TSX:<a class="ticker" href="https://www.benzinga.com/stock/RSI#TSX">RSI</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.15 by 13.33 percent. This is a 23.53 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $326.31 million which beat the analyst consensus estimate of $323.43 million by 0.89 percent. This is a 8.43 percent increase over sales of $300.94 million the same period last year.

TSX:RSI

Rogers Sugar Q2 Adj. EPS $0.13 Misses $0.15 Estimate, Sales $326.31M Beat $323.43M Estimate

CODA

Coda Octopus Secures $1.5M US Navy Order For DAVD Tethered Systems With Echoscope, Highlighting Continued Investment in Subsea Tech

Latest MES release helps pharmaceutical and biopharmaceutical manufacturers simplify system management, improve flexibility and speed time-to-value
MILWAUKEE, May 13, 2025 /PRNewswire/ --&nbsp;<a href="https://www.rockwellautomation.com/">Rockwell Automation, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>), the world's largest company dedicated to industrial automation and digital transformation, today announced the launch of <a href="https://www.rockwellautomation.com/en-us/products/software/factorytalk/operationsuite/mes/life-sciences.html">FactoryTalk&#xAE; PharmaSuite&#xAE; 12.00</a>. The latest release of its manufacturing execution system (MES) is designed to support the unique needs of regulated pharmaceutical and biopharmaceutical manufacturing environments, helping companies simplify system management, accelerate deployments and scale production more efficiently.

Rockwell Automation Launches FactoryTalk PharmaSuite 12.00 To Simplify System Management, Accelerate Deployments And Scale Production More Efficiently

Toyota continues to move its electrified vehicle portfolio forward by announcing its 2026 bZ Battery Electric Vehicle (BEV). For model year 2026, the model makes advancements in range, output, charging performance, and vehicle design. Leading the charge is a larger lithium-ion battery with a higher total capacity of up to 74.7-kWh, equipped on a newly available XLE Front-Wheel-Drive Plus (FWD Plus) model, as well as the XLE All-Wheel-Drive (AWD) and Limited (FWD/AWD) grades. Models equipped with the new battery are projected to have a manufacturer-estimated rating of&nbsp;up to 314 miles&#x2A; of range on a full charge. A 57.7-kWh battery will also be available on a XLE FWD model.
&nbsp;
The 2026 bZ will be equipped with a North American Charging System (NACS) charging port, giving it access to thousands of high-speed charging stations nationwide. Under ideal conditions when using DC fast charging&#x2A; it is capable of charging from 10% to-80% battery capacity in around 30 minutes. The 2026 Toyota bZ also adopts <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4425982-1&amp;h=1118701590&amp;u=https%3A%2F%2Fdriveelectric.gov%2Fnews%2Funiversal-plug-and-charge&amp;a=Plug+%26+Charge">Plug &amp; Charge</a>&nbsp;capability, an industry standard protocol that allows automatic identification, authentication and authorization at selected charging networks, reducing the need for multiple mobile charging applications.
Toyota's compact, lightweight and energy-efficient eAxles have also been upgraded. They now use silicon carbide (SIC) semiconductors, which help deliver higher power output. For AWD models, output increases by 50% to 338 combined system net horsepower (hp), making it capable of going from 0-60 MPH in 4.9 seconds on AWD models. Front Wheel Drive models also boost their output, now delivering up-to 221 hp (previously 201 hp). For AWD models, output increases by 50% to 338 combined system net horsepower (hp), making it capable of going from 0-60 MPH in around 5 seconds. Front Wheel Drive models also boost their output, now delivering up-to 221 hp (previously 201 hp).
The model also receives a name change, switching from the Toyota bZ4X to the Toyota bZ, simplifying the name for customers. The 2026 bZ also presents a refreshed exterior design that harmoniously blends form and function. While maintaining its distinctive aesthetic, the updated model incorporates subtle refinements to the front fascia and lighting elements, with slim LED daytime running lights that integrate into a sleek hammerhead front end. Redesigned front overfenders also change the look, with a newly available color-matched moulding that blends into a lower profile front fascia.

Toyota Unveils 2026 bZ EV With 314-Mile Range, Faster Charging, and Sleek New Look

Under the terms of the agreement, $15 million will be drawn at closing. An additional $25 million is available in 2025 at Altimmune's option, subject to certain clinical and financial milestones. The remaining $60 million is available beginning in 2026, with $15 million subject to the achievement of certain clinical and financial milestones and up to $45 million available subject to the approval of Hercules. The facility is structured as interest only for the first 24 months, extendable up to 42 months on achievement of milestones. The loan matures 48 months from closing, and no warrants are included in the agreement.
 &nbsp;

Financing

Altimmune Secures Up To $100M In Credit Facility From Hercules Capital

SLAB

Silicon Laboratories Sees Q2 Adj EPS $(0.01)-$0.19 vs $(0.09) Est; Sees Sales $185.000M-$200.000M vs $177.49M Est

Press Releases

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

Comments

Vir Biotechnology

Noticias

Últimas noticias sobre Vir Biotechnology (NASDAQ:VIR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL